Literature DB >> 17366789

[Expression of CD80, CD86, TGF-beta1 and IL-10 mRNA in the esophageal carcinoma].

Wen-Feng Yang1, Jin-Ming Yu, Wen-Shu Zuo, Shan-Zheng Wang.   

Abstract

OBJECTIVE: To investigate the correlation of CD80 and CD86 mRNA expression with the expression of transforming growth factor-beta1 mRNA (TGF-beta1) and interleukin-10 mRNA (IL-10) in the esophageal cancer. To explore the reason of impaired immunological function of dentritic cell (DC) and the mechanism of cancer cell escaption from body immunity system in the esophageal cancer patient.
METHODS: Expression of CD80, CD86, TGF-beta1 and IL-10R mRNA was detected by reverse transcription polymerase chain reaction (RT-PCR) in specimens of 62 esophageal carcinoma and 16 normal esophageal mucosal tissues used as normal control.
RESULTS: Expression of CD80 and CD86 mRNA in the esophageal cancer tissue was significantly lower than that in the normal esophageal mucosal tissue (CD80: P = 0.038; CD86: P = 0.0002). It was significantly higher in stage I or II than that in stage III or IV (CD80: P = 0.029; CD86: P = 0.045); and also higher in paitents with high or moderate differentiation than that with poor differentiation (CD80: P = 0.046; CD86: P = 0.044). Furthermore, it was found to be reversely correlated with expression of TGF-beta1, IL-10 mRNA by multiple regression analysis (P = 0. 0001) respectively, the more TGF-beta1 and IL-10 mRNA expressed in the tumor tissue, the less CD80 and CD86 mRNA expressed by dendritic cells.
CONCLUSION: The expression of CD80 and CD86 mRNA in the tissues of esophageal cancer are found to be weak, and reversely correlated with the expression of TGF-beta1 and IL-10 mRNA. High level expression of TGF-beta1 and IL-10 mRNA may be an important influential factor to the weak expression of CD80 and CD86 mRNA, which may be one of the reasons leading to impaired function of dendritic cells and immune escape of cancer cells in the esophageal cancer patient.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17366789

Source DB:  PubMed          Journal:  Zhonghua Zhong Liu Za Zhi        ISSN: 0253-3766


  6 in total

1.  Overexpression and interactions of interleukin-10, transforming growth factor beta, and vascular endothelial growth factor in esophageal squamous cell carcinoma.

Authors:  Mehran Gholamin; Omeed Moaven; Bahram Memar; Moein Farshchian; Hossein Naseh; Reza Malekzadeh; Masoud Sotoudeh; Mohammad Taghi Rajabi-Mashhadi; Mohammad Naser Forghani; Farid Farrokhi; Mohammad Reza Abbaszadegan
Journal:  World J Surg       Date:  2009-07       Impact factor: 3.352

2.  TGF-β1 polymorphisms -509 C>T and +915 G>C and risk of pancreatic cancer.

Authors:  Faegheh Behboudi Farahbakhsh; Ehsan Nazemalhosseini Mojarad; Pedram Azimzadeh; Faezeh Goudarzi; Amir Houshang Mohammad Alizadeh; Mehrdad Haghazali; Reza Mahmoudi Lamoki; Hamid Asadzadeh Aghdaei
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2017

3.  PD-L1 expression, CD8+ and CD4+ lymphocyte rate are predictive of pathological complete response after neoadjuvant chemoradiotherapy for squamous cell cancer of the thoracic esophagus.

Authors:  Matteo Fassan; Francesco Cavallin; Vincenza Guzzardo; Andromachi Kotsafti; Melania Scarpa; Matteo Cagol; Vanna Chiarion-Sileni; Luca Maria Saadeh; Rita Alfieri; Ignazio Castagliuolo; Massimo Rugge; Carlo Castoro; Marco Scarpa
Journal:  Cancer Med       Date:  2019-08-20       Impact factor: 4.452

Review 4.  The immune landscape of esophageal cancer.

Authors:  Tu-Xiong Huang; Li Fu
Journal:  Cancer Commun (Lond)       Date:  2019-11-26

Review 5.  Immunotherapy resistance in esophageal cancer: Possible mechanisms and clinical implications.

Authors:  Pinhao Fang; Jianfeng Zhou; Zhiwen Liang; Yushang Yang; Siyuan Luan; Xin Xiao; Xiaokun Li; Hanlu Zhang; Qixin Shang; Xiaoxi Zeng; Yong Yuan
Journal:  Front Immunol       Date:  2022-09-02       Impact factor: 8.786

6.  Immune surveillance activation after neoadjuvant therapy for esophageal adenocarcinoma and complete response.

Authors:  Andromachi Kotsafti; Melania Scarpa; Francesco Cavallin; Matteo Fassan; Roberta Salmaso; Andrea Porzionato; Luca Saadeh; Matteo Cagol; Rita Alfieri; Carlo Castoro; Massimo Rugge; Ignazio Castagliuolo; Marco Scarpa
Journal:  Oncoimmunology       Date:  2020-08-12       Impact factor: 8.110

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.